MDMA and prosocial behavior

This interventional trial (n=18; status unknown) aims to explore the impact of oxytocin and the 5-HT1A receptor on MDMA-induced prosocial behaviour.

Led by Dr. Kim Kuypers at Maastricht University, the study is supported by the Netherlands Organisation for Scientific Research (NWO).

Over four treatment sessions, participants will receive different combinations of treatments including MDMA, oxytocin, and placebo, with a minimum 7-day washout period between sessions. The study will assess social behaviour, mood, and treatment concentrations in the blood.

Researchers hypothesize that oxytocin mimics MDMA’s prosocial effects and that the 5-HT1A receptor mediates these effects. Eligible participants, aged 18-40 with MDMA experience, will undergo medical screening and training on computer tasks.

The total study duration is approximately 18.5 hours spread over at least 5 weeks. Recruitment is pending, with an anticipated start date of February 2011 and an enrollment target of 18 participants.

Topic Healthy Subjects
Compound Placebo MDMA
Country Netherlands
Visit trial
Status Unknown status
Results Published No
Start date 01 February 2011
End date 31 December 2014
Design Blinded
Type Interventional
Generation First
Participants 18
Sex All
Age 18- 40
Therapy No

Trial Details

This interventional trial (n=18) led by Dr. Kim Kuypers at Universiteit Maastricht investigates the impact of oxytocin and the 5-HT1A receptor on MDMA-induced prosocial behaviour. Participants receive different treatments including MDMA, oxytocin, and placebo over four sessions, with a minimum 7-day gap. The study aims to understand how oxytocin and the 5-HT1A receptor influence prosocial effects. Recruitment is pending, with an anticipated start date of February 2011 and an enrollment target of 18 participants.

NCT Number NL34859.068.10

Sponsors & Collaborators

Maastricht University
Maastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.